JumpStart®

ADVANCED
MICROCURRENT
TECHNOLOGY®





- Kills and protects against certain gram-positive and gram-negative bacteria[1-4]
- Water resistant; 7-day wear time
- Buildable to cover incisions of any length and angle

Click to learn more about JumpStart dressings
https://www.arthrex.com/orthobiologics/jumpstart

Arthrex®

Quick Facts

JumpStart® Surgical Site Infections (SSI)

ADVANCED MICROCURRENT HEALING™

Persistent, costly, and preventable

Occur in
1% to 2%
of all patients worldwide undergoing inpatient surgery[5-7]

Affect
millions
of patients each year

USA: 1.5 million[8]
Europe: 500,000[6]

Increase annual treatment costs
USA:
+$3.5 to $10 billion[9]
Europe:
+€1.5 to €19 billion[10]

Prolong hospitalization
USA: +9.7 days[9]
Europe: +6.5 days[10]

3% estimated mortality rate with SSI[8]

75% of SSI-associated deaths are directly attributable to the infection[8]

Specific Surgery	Overall Incidence of SSI	Incidence of SSI in High-risk Patients
Colon surgery	6.1%[12]	13.6%[12]
Coronary artery bypass graft	3.9%[13]	13%[13]
Caesarean section	2.9%[8]	11.7%[8]
Laminectomy	0.72%[14]	2.3%[14]
Spinal fusion	0.7%[14]	4.15%[14]
Hip prosthesis	0.67%[14]	2.4%[14]
Knee prosthesis	0.58%[14]	1.6%[14]

50% of SSI are preventable[5-6,11]

Reduce the Risk of SSI

JumpStart antimicrobial wound dressing kills a broad spectrum of microbes, including multidrug-resistant and biofilm-forming bacteria[1,3,15]

References

1. Banerjee J, Das Ghatak P, Roy S, et al. Silver-zinc redox-coupled electroceutical wound dressing disrupts bacterial biofilm. *PLoS One.* 2015;10(3):e0119531. doi:10.1371/journal.pone.0119531 **2.** Kim H, Makin I, Skiba J. Antibacterial efficacy testing of a bioelectric wound dressing against clinical wound pathogens. *Open Microbiol J.* 2014;8:15-21. doi:10.2174/1874285801408010015 **3.** Kim H, Izadjoo MJ. Antibiofilm efficacy evaluation of a bioelectric dressing in mono-and multi-species biofilms. *J Wound Care.* 2015;24(Suppl 2):S10-4. doi:10.12968/jowc.2015.24.Sup2.S10 **4.** Long DR, Bryson-Cahn C, Pergamit R, et al. 2021 Young Investigator Award winner: anatomic gradients in the microbiology of spinal fusion surgical site infection and resistance to surgical antimicrobial prophylaxis. *Spine.* 2021;46(3):143-151. doi:10.1097/BRS.0000000000003603 **5.** Keely Boyle K, Rachala S, Nodzo SR. Centers for Disease Control and Prevention 2017 guidelines for prevention of surgical site infections: review and relevant recommendations. *Curr Rev Musculoskelet Med.* 2018;11(3):357-369. doi:10.1007/s12178-018-9498-8 **6.** WHO global guidelines for the prevention of surgical site infection. World Health Organization. Accessed May 2, 2023. https://www.who.int/publications/i/item/global-guidelines-for-the-prevention-of-surgical-site-infection-2nd-ed **7.** Klevens RM, Edwards JR, Richards CL Jr, et al. Estimating health care-associated infections and deaths in U.S. hospitals, 2002. *Public Health Rep.* 2007;122(2):160-166. doi:10.1177/003335490712200205 **8.** MA Preas, O'Hara L, Thom K. HICPAC-CDC guideline for prevention of surgical site infection: what the infection preventionist needs to know. Association for Professionals in Infection Control and Epidemiology. Accessed May 2, 2023. https://apic.org/Resource_/TinyMceFileManager/Periodical_images/API-Q0414_L_SSI_Guidelines_Final.pdf **9.** RD Scott. The direct medical costs of healthcare-associated infection in U.S. hospitals and the benefits of prevention. Centers for Disease Control and Prevention. Accessed May 2, 2023. https://www.cdc.gov/hai/pdfs/hai/scott_costpaper.pdf **10.** Leaper DJ, van Goor H, Reilly J, et al. Surgical site infection - a European perspective of incidence and economic burden. Int Wound J. 2004;1(4):247-273. doi:10.1111/j.1742-4801.2004.00067.x Surveillance of surgical site infections in Europe 2010-20 **11.** European Centre for Disease Prevention and Control. Accessed May 2, 2023. https://www.ecdc.europa.eu/sites/portal/files/media/en/publications/Publications/SSI-in-europe-2010-2011.pdf **12.** Amri R, Dinaux AM, Kunitake H, Bordeianou LG, Berger DL. Risk stratification for surgical site infections in colon cancer. *JAMA Surg.* 2017;152(7):686–690. doi:10.1001/jamasurg.2017.0505 **13.** Rochon M, Jarman JW, Gabriel J, et al. Multi-centre prospective internal and external evaluation of the Brompton Harefield Infection Score (BHIS). J Infect Prev. 2018;19(2):74-79. doi:10.1177/1757177417733062 **14.** Guide to the elimination of orthopedic surgical site infections: an APIC guide. Association for Professionals in Infection Control and Epidemiology. Accessed May 2, 2023. https://apic.org/wp-content/uploads/2019/10/APIC-Ortho-Guide.pdf **15.** Kim H, Makin I, Skiba J, et al. Antibacterial efficacy testing of a bioelectric wound dressing against clinical wound pathogens. *Open Microbiol J.* 2014;8:15-21. doi:10.2174/1874285801408010015

arthrex.com

Arthrex®